Author

admin

Browsing

InMed Pharmaceuticals (NASDAQ: INM) pairs innovative therapeutic development in Alzheimer’s, ophthalmology, and dermatology with recurring revenue from its BayMedica manufacturing division — giving investors rare small-cap biotech exposure to high-impact science with reduced financing risk. INM-901 takes a multi-pathway approach to Alzheimer’s, targeting several core drivers of the disease rather…